公开(公告)号：US20190233426A1

公开(公告)日：2019-08-01

申请号：US16311575

申请日：2017-06-09

Applicant: Novartis AG

Inventor： Ho Man CHAN ,  Xingnian Fu ,  Xiang-Ju Justin Gu ,  Ying HUANG ,  Ling LI ,  Yuan MI ,  Wei QI ,  Martin SENDZIK ,  Yongfeng SUN ,  Long WANG ,  Zhengtian YU ,  Hailong ZHANG ,  Ji Yue ZHANG ,  Man ZHANG ,  Qiong ZHANG ,  Kehao ZHAO

IPC: C07D487/04 ,  A61P35/00

Abstract: A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R3, R4, R6, and R7 are as defined herein.

公开(公告)号：US20240216378A1

公开(公告)日：2024-07-04

申请号：US18423776

申请日：2024-01-26

Applicant: NOVARTIS AG

Inventor： Ho Man CHAN ,  Xiang-Ju Justin GU ,  Ying HUANG ,  Ling LI ,  Yuan MI ,  Wei QI ,  Martin SENDZIK ,  Yongfeng SUN ,  Long WANG ,  Zhengtian YU ,  Hailong ZHANG ,  Ji Yue (Jeff) ZHANG ,  Man ZHANG ,  Qiong ZHANG ,  Kehao ZHAO

IPC: A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551 ,  A61K45/06 ,  C07D487/04

CPC classification number: A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551 ,  A61K45/06 ,  C07D487/04

Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder:






wherein R1, R2, R3, R4, R5, and n are as defined herein.

公开(公告)号：US20190202828A1

公开(公告)日：2019-07-04

申请号：US16311621

申请日：2017-06-06

Applicant: Novartis AG

Inventor： Ho Man CHAN ,  Xingnian Fu ,  Xiang-Ju Justin Gu ,  Ying HUANG ,  Ling LI ,  Yuan MI ,  Wei QI ,  Martin SENDZIK ,  Yongfeng SUN ,  Long WANG ,  Zhengtian YU ,  Hailong ZHANG ,  Ji Yue ZHANG ,  Man ZHANG ,  Qiong ZHANG ,  Kehao ZHAO

IPC: C07D471/04 ,  A61P35/00

Abstract: A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R6, R7 and R8 are as defined herein.

公开(公告)号：US20190142837A1

公开(公告)日：2019-05-16

申请号：US16246380

申请日：2019-01-11

Applicant: Novartis AG

Inventor： Ho Man CHAN ,  Xiang-Ju Justin GU ,  Ying HUANG ,  Ling LI ,  Yuan MI ,  Wei QI ,  Martin SENDZIK ,  Yongfeng SUN ,  Long WANG ,  Zhengtian YU ,  Hailong ZHANG ,  Ji Yue (Jeff) ZHANG ,  Man ZHANG ,  Qiong ZHANG ,  Kehao ZHAO

IPC: A61K31/519 ,  A61K45/06 ,  A61K31/551 ,  C07D487/04 ,  A61K31/5377 ,  A61K31/541

Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.

公开(公告)号：US20230033320A1

公开(公告)日：2023-02-02

申请号：US17505271

申请日：2021-10-19

Applicant: Novartis AG

Inventor： Ho Man CHAN ,  Xiang-Ju Justin GU ,  Ying HUANG ,  Ling LI ,  Yuan MI ,  Wei QI ,  Martin SENDZIK ,  Yongfeng SUN ,  Long WANG ,  Zhengtian YU ,  Hailong ZHANG ,  Ji Yue (Jeff) ZHANG ,  Man ZHANG ,  Qiong ZHANG ,  Kehao ZHAO

IPC: A61K31/519 ,  C07D487/04 ,  A61K45/06 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551

Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.

公开(公告)号：US20200323859A1

公开(公告)日：2020-10-15

申请号：US16863631

申请日：2020-04-30

Applicant: Novartis AG

Inventor： Ho Man CHAN ,  Xiang-Ju Justin GU ,  Ying HUANG ,  Ling LI ,  Yuan MI ,  Wei QI ,  Martin SENDZIK ,  Yongfeng SUN ,  Long WANG ,  Zhengtian YU ,  Hailong ZHANG ,  Ji Yue (Jeff) ZHANG ,  Man ZHANG ,  Qiong ZHANG ,  Kehao ZHAO

IPC: A61K31/519 ,  C07D487/04 ,  A61K45/06 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551

Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.